COVID-19 va yurak ishimik kasalligi birgalikda kechganda  kilinik  xususiyatlarni o‘rganish

Barchinoy Tog‘ayeva; Mohigul Bekkulova; Akmaljon Baxronov; Zuhra Safarova; Gulshoda O‘roqova; Aziza Xaydarova

doi:10.47689/2181-3663-vol4-iss4-pp224-229

Barchinoy Togaeva Assistant, Department of Internal Medicine and Cardiology No.2, Samarkand State Medical University
Mokhikul Bekkulova Assistant, Department of Propaedeutics of Internal Medicine, Fergana Medical Institute of Public Health
Akmaljon Bakhronov 1st year resident, Assistant, Department of Internal Medicine and Cardiology No.2, Samarkand State Medical University
Zukhra Safarova Student, Faculty of Medicine, Samarkand State Medical University
Gulshoda Urokova Student, Faculty of Medicine, Samarkand State Medical University
Aziza Khaydarova Resuscitation doctor, Samarkand branch of the Republican Center for Emergency Medical Care

DOI

https://doi.org/10.47689/2181-3663-vol4-iss4-pp224-229

Keywords

COVID-19 , ischemic heart disease , cardiovascular system

Abstract

The COVID-19 pandemic has infected nearly 600 million people worldwide, becoming a global health emergency and killing nearly 6 million people, with lung damage and increased morbidity in those with comorbid conditions. According to an international meta-analysis of 192 studies from around the world, 7.4% of patients with COVID-19 were hospitalized with pneumonia, 13.4% with acute respiratory distress syndrome; 3.3% were admitted to the intensive care unit, of which 1.6% required mechanical ventilation, and the mortality rate was 0.8%. In addition, scientists note that patients with cardiovascular diseases are at increased risk of COVID-19 infection and that the new coronavirus infection is likely to have a negative impact on the cardiovascular system. Cardiovascular diseases have been recognized as a factor aggravating the consequences of infection during the COVID-19 pandemic.

References

Тогаева Б. и др. COVID-19 YURAK QON TOMIR KASALLIKLARI BOR BEMORLARDA KECHISHI //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2. – С. 47-50.

Khasanjanova F. O., Khaydarova D. D., Togayeva B. M. To study the frequency of the risk factors of smoking in patients with acute coronary syndrome in young age //Science, Research, Development. – Т. 33. – С. 29-30.

Togaeva B. et al. OCCURRENCE OF SARS–COV-2 DISEASE (COVID-19) AND IN PATIENTS WITH CARDIOVASCULAR DISEASES //InterConf. – 2021.

Ташкенбаева Э. Н. и др. Связь тяжести хронической сердечной недостаточности от локализации острого инфаркта миокарда //Наука и современное общество: взаимодействие и развитие. – 2018. – Т. 2. – №. 1. – С. 36-38.

Мухиддинов А. И. и др. Клиническая характеристика прогрессирования артериальной гипертонии с риском сердечно сосудистых осложнений при СOVID-19 //Polish Science Journal. – №. 1. – С. 34.

Пулатова, Н. И., Якубов, А. В., & Хамраев, А. А. (2012). Оценка фармакодинамического эффекта препаратов и стандартных схем терапии второй линии язвенной болезни на показатели NO-системы и анаэробного гликолиза в слизистой ткани желудка. Врач-аспирант, 50(1.2), 296-302.

МУХИДДИНОВ А. И. и др. COVID-19 БИЛАН ОҒРИГАН БЕМОРЛАРДА ГИПЕРТОНИЯ КАСАЛЛИГИ ЎПКАНИНГ СУРУНКАЛИ ОБСТРУКТИВ КАСАЛЛИГИНИНГ КОМОРБИДЛИГИДА КЛИНИК КЕЧИШИНИНГ ЎЗИГА ХОСЛИГИ ВА ЗАМОНАВИЙ ДИАГНОСТИКАСИ //ЖУРНАЛ БИОМЕДИЦИНЫ И ПРАКТИКИ. – 2022. – Т. 7. – №. 4.

Халилов Н. Х. и др. Особенности Течения Гипертонических Кризов И Их Осложнений В Условиях Экстренной Медицинской Помощи //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2022. – Т. 3. – №. 1. – С. 44-46.

Ташкенбаева Э. Н., Мухиддинов А. И., Тогаева Б. М. ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ У ЛИЦ МОЛОДОГО ВОЗРАСТА //ТОМ–III. – 2019. – С. 359.

Ташкенбаева Э. и др. РАСПРОСТРАНЕННОСТЬ МЕТАБОЛИЧЕСКОГО СИНДРОМА У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 1. – С. 85-88.

Downloads

PDF (O'zbek)

36 17

Published

2025-10-25

How to Cite

Togaeva, B., Bekkulova, M., Bakhronov, A., Safarova, Z., Urokova , G. and Khaydarova, A. 2025. Study of clinical features of COVID-19 and coexisting heart disease. Preventive Medicine and Health. 4, 4 (Oct. 2025), 224–229. DOI:https://doi.org/10.47689/2181-3663-vol4-iss4-pp224-229.